

# Problem, Reaction, Solution: Does the Gates Foundation “Own the Coronavirus Patent”?


By [Mark Taliano](#)

Global Research, May 14, 2020

[Mark Taliano](#)

Bill and Melinda Gates, “major stakeholders” in the Pirbright Institute, “own” the identified problem, which is the coronavirus.

...



The patent, pictured below, was acquired on November 20, 2018.

(12) **United States Patent**  
**Bickerton et al.**

(10) **Patent No.:** **US 10,130,701 B2**  
(45) **Date of Patent:** **Nov. 20, 2018**

(54) **CORONAVIRUS**

**OTHER PUBLICATIONS**

(71) Applicant: **THE PIRBRIGHT INSTITUTE**,  
Pirbright, Woking (GB)  
(72) Inventors: **Erica Bickerton**, Woking (GB); **Sarah  
Keep**, Woking (GB); **Paul Britton**,  
Woking (GB)  
(73) Assignee: **THE PIRBRIGHT INSTITUTE**,  
Woking, Pirbright (GB)  
(\*) Notice: Subject to any disclaimer, the term of this  
patent is extended or adjusted under 35  
U.S.C. 154(b) by 0 days.

*Spony Journal of Virology*, 2005, vol. 79, No. 6, pp. 3391-3400.\*  
Altschul et al., Basic local alignment search tool, *J. Mol. Biol.* 215:  
403-410 (1990).  
Anthonysoppan et al., Identification of sequence changes respon-  
sible for the attenuation of avian infectious bronchitis virus strain  
Arkansas DPL, *Arch. Virol.* 154(3):495-9 (2009).  
Anonymous, "EM STD-KF377577", Oct. 30, 2013.  
Armato et al., A recombinant avian infectious bronchitis virus  
expressing a heterologous spike gene belonging to the 491 serotype,  
PLoS One, 6(8):e24352 (2011).  
Armato et al., The replicase gene of avian coronavirus infectious  
bronchitis virus is a determinant of pathogenicity, *PLoS One*,  
4(10):e7384 (2009).  
Armato et al., Transient dominant selection for the modification  
and generation of recombinant infectious bronchitis coronaviruses,  
Methods Mol. Biol., 454:255-73 (2008).  
Ausubel et al., Short Protocols in Molecular Biology, 4th edition,  
Chapter 18 (1999).  
Britton et al., Generation of a recombinant avian coronavirus  
infectious bronchitis virus using transient dominant selection, *J.*  
*Virol. Methods*, 123(2):201-11 (2005).  
Britton et al., Modification of the avian coronavirus infectious  
bronchitis virus for vaccine development, *Bioeng. Bugs*, 3(2):114-9  
(2012).  
Cassin et al., Recombinant avian infectious bronchitis virus expres-  
sing a heterologous spike gene demonstrates that the spike protein is  
a determinant of cell tropism, *J. Virol.*, 75(16):9044-9 (2001).  
Cassin et al., Reverse genetics system for the avian coronavirus  
infectious bronchitis virus, *J. Virol.*, 75(24):12359-69 (2001).  
Deveron et al., A comprehensive set of sequence analysis programs  
for the VAX, *Nucl. Acids Res.* 12: 387-95 (1984).  
Cavanagh et al., Manipulation of the infectious bronchitis coronavirus  
genome for vaccine development and analysis of the accessory  
proteins, *Vaccine*, 25(30):5158-62 (2007).  
International Preliminary Report on Patentability, International Appli-  
cation No. PCT/GB2015/052124, dated Jan. 24, 2017.  
International Search Report and Written Opinion, International  
Application No. PCT/GB2015/052124, dated Oct. 9, 2015.  
Larkin et al., Clustal W and Clustal X version 2.0, *Bioinformatics*,  
23(21):2947-8 (2007).  
Mansbury et al., Attenuation and restoration of acute acute  
respiratory syndrome coronavirus mutant lacking 2'-O-  
methyltransferase activity, *J. Virol.*, 88(8):4251-64 (2014).  
Tatusova et al., BLAST 2 Sequences, a new tool for comparing  
protein and nucleotide sequences, *FEMS Microbiol. Lett.*, 174(2):247-  
50 (1999).

(Continued)

(21) Appl. No.: **15/328,179**  
(22) PCT Filed: **Jul. 23, 2015**  
(86) PCT No.: **PCT/GB2015/052124**  
§ 371 (a)(1).  
(2) Date: **Jan. 23, 2017**  
(87) PCT Pub. No.: **WO2016/012793**  
PCT Pub. Date: **Jan. 28, 2016**

(65) **Prior Publication Data**

US 2017/0216427 A1 Aug. 3, 2017

(30) **Foreign Application Priority Data**

Jul. 23, 2014 (GB) ..... 1413020.7

(51) **Int. Cl.**  
**A61K 39/215** (2006.01)  
**C12N 7/00** (2006.01)  
**C12N 9/12** (2006.01)  
**A61K 39/00** (2006.01)

(52) **U.S. Cl.**  
CPC ..... **A61K 39/215** (2013.01); **C12N 7/00**  
(2013.01); **C12N 9/127** (2013.01); **C12F**  
**205/07048** (2013.01); **A61K 2039/5254**  
(2013.01); **A61K 2039/54** (2013.01); **C12N**  
**2779/20021** (2013.01); **C12N 2779/20022**  
(2013.01); **C12N 2779/20034** (2013.01); **C12N**  
**2779/20051** (2013.01); **C12N 2779/20062**  
(2013.01)

(58) **Field of Classification Search**  
CPC ..... **A61K 39/215**  
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

*Primary Examiner*—Hao Q Li  
(74) *Attorney, Agent, or Firm*—Marshall, Gerstein &  
Boran LLP

(57) **ABSTRACT**

The present invention provides a live, attenuated coronavirus

Coronavirus patent owned by Pirbright Institute

Mark Tallano's Photos  
ome > Results > **EP3172319A1**

☆ **EP3172319A1 CORONAVIRUS**

**Bibliographic data** Description Claims Drawings Original document C

Register ↗ ⓘ **Global Dossier** ↗

Applicants THE PIRBRIGHT INST [GB] +

Inventors BICKERTON ERICA [GB]; BRITTON PAUL [GB]; KEEP SARAH [GB]

This patent is owned by a  
company called the Pirbright Institute.

TRAITS TO  
SUCCESS  
TRANSFORMING  
LIVES

Classifications Options

at 39,000 results (0.44 seconds)

.gatesfoundation.org › Grants › 2013/11 › OPP1098099 ▼

## Pirbright Institute - Bill & Melinda Gates

Pirbright Institute. Date: November 2013. Purpose: to improve the effective use of, current control tools and measures (including .

Oh, look at this: Pirbright Institute-  
Bill & Melinda Gates Foundation...



.pirbright.ac.uk › partnerships › our-major-stakeholders

Not only do they own the “problem”, but they also have vested interests in the “solution”. The proposed “solution” is the vaccine.

Watch the video below by Dr. Rashid Buttar.



The original source of this article is [Mark Taliano](#)  
Copyright © [Mark Taliano](#), [Mark Taliano](#), 2020

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Mark Taliano](#)

**Disclaimer:** The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: [publications@globalresearch.ca](mailto:publications@globalresearch.ca)

[www.globalresearch.ca](http://www.globalresearch.ca) contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: [publications@globalresearch.ca](mailto:publications@globalresearch.ca)